Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
The study is performed to collect long-term data on the treatment adherence and patient's
 acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in
 patients with a growth hormone deficiency or Turner's syndrome.
Inclusion Criteria:

 -  Patient with growth hormone deficiency,

 1. Diagnosis of growth hormone deficiency proven by appropriate exploration

 2. Size ≤ -2 Standard Deviation (SD) according to the French references

 3. Growth velocity in the previous year inferior to the normal for age (-1SD) or <
 4cm/year

 -  Growth deficiency due to Turner's syndrome

 1. Turner's syndrome confirmed by a karyotype

 2. Patient's size ≤ -2 SD according to the French references

 3. Bone age < 12 years

 -  Patient who require a minimum of 18 months of treatment.

 Exclusion Criteria:

 -  There are no exclusion criteria except the contraindication for Zomacton® 10 mg